ProfileGDS5678 / 1415865_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 78% 81% 77% 81% 74% 78% 80% 77% 78% 78% 76% 78% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.458179
GSM967853U87-EV human glioblastoma xenograft - Control 25.4700378
GSM967854U87-EV human glioblastoma xenograft - Control 35.7738481
GSM967855U87-EV human glioblastoma xenograft - Control 45.4429777
GSM967856U87-EV human glioblastoma xenograft - Control 55.7875681
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7851874
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2548978
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6362680
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2167777
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3619778
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3332278
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1682576
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3840478
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3197278